also observed that CSF p‐tau217 correlates stronger than CSF p‐tau181 with PET measures of tau and amyloid pathologies in AD and hypothesized that p‐tau217 levels may reflect the pathological state of tau better than p‐tau181 levels, although the sensitivity of p‐tau is highly dependent on the performance of antibodies (e.g., anti‐p‐tau217 antibody IBA413 and anti‐p‐tau181 antibody AT270) [54]. The gene discussed is MAPT; the disease is Alzheimer disease.